Esperion Therapeutics (NASDAQ:ESPR) had its price objective hoisted by Stifel Nicolaus from $89.00 to $104.00 in a research report sent to investors on Monday morning, The Fly reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other research reports. Citigroup raised shares of Esperion Therapeutics from a neutral rating to a buy rating and upped their price objective for the company from $57.00 to $75.00 in a report on Friday, August 17th. BidaskClub lowered shares of Esperion Therapeutics from a hold rating to a sell rating in a report on Saturday, September 22nd. Zacks Investment Research raised shares of Esperion Therapeutics from a hold rating to a buy rating and set a $51.00 price objective for the company in a report on Wednesday, October 3rd. BTIG Research assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, October 16th. They issued a buy rating and a $82.00 price objective for the company. Finally, Cowen set a $82.00 price objective on shares of Esperion Therapeutics and gave the company a buy rating in a report on Friday, October 26th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $77.04.

Esperion Therapeutics stock opened at $55.12 on Monday. Esperion Therapeutics has a 52-week low of $33.06 and a 52-week high of $82.68. The firm has a market cap of $1.42 billion, a PE ratio of -7.90 and a beta of 2.36.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.58) by ($0.28). During the same period last year, the firm earned ($1.86) EPS. As a group, equities research analysts forecast that Esperion Therapeutics will post -6.59 EPS for the current fiscal year.

In other Esperion Therapeutics news, Director Roger S. Newton sold 9,400 shares of the company’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $50.01, for a total value of $470,094.00. Following the transaction, the director now owns 589,326 shares of the company’s stock, valued at $29,472,193.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Roger S. Newton sold 2,827 shares of the company’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $50.07, for a total transaction of $141,547.89. Following the completion of the transaction, the director now directly owns 573,953 shares in the company, valued at approximately $28,737,826.71. The disclosure for this sale can be found here. Insiders sold 152,327 shares of company stock valued at $8,463,042 in the last three months. 14.50% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BTG Pactual Global Asset Management Ltd lifted its position in Esperion Therapeutics by 20.2% in the second quarter. BTG Pactual Global Asset Management Ltd now owns 8,719 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 1,465 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its position in Esperion Therapeutics by 40.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 2,224 shares during the last quarter. Creative Planning lifted its position in Esperion Therapeutics by 42.0% in the third quarter. Creative Planning now owns 7,562 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 2,236 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Esperion Therapeutics by 3.4% in the third quarter. JPMorgan Chase & Co. now owns 71,095 shares of the biopharmaceutical company’s stock valued at $3,155,000 after buying an additional 2,348 shares during the last quarter. Finally, Bailard Inc. lifted its position in Esperion Therapeutics by 50.0% in the second quarter. Bailard Inc. now owns 9,000 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 3,000 shares during the last quarter.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: Institutional Investors

The Fly

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.